Ascendis Pharma AS (ASND)
126.51
+2.23
(+1.79%)
USD |
NASDAQ |
Nov 15, 16:00
126.56
+0.04
(+0.04%)
After-Hours: 20:00
Ascendis Pharma Research and Development Expense (TTM): 385.87M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 385.87M |
| March 31, 2024 | 410.50M |
| December 31, 2023 | 447.69M |
| September 30, 2023 | 460.89M |
| June 30, 2023 | 437.70M |
| March 31, 2023 | 419.46M |
| December 31, 2022 | 398.84M |
| September 30, 2022 | 362.86M |
| June 30, 2022 | 333.99M |
| March 31, 2022 | 338.12M |
| December 31, 2021 | 350.99M |
| September 30, 2021 | 366.22M |
| June 30, 2021 | 371.85M |
| March 31, 2021 | 341.47M |
| December 31, 2020 | 298.72M |
| September 30, 2020 | 264.07M |
| June 30, 2020 | 240.60M |
| March 31, 2020 | 219.81M |
| December 31, 2019 | 214.57M |
| September 30, 2019 | 202.25M |
| Date | Value |
|---|---|
| June 30, 2019 | 187.45M |
| March 31, 2019 | 186.26M |
| December 31, 2018 | 165.55M |
| September 30, 2018 | 155.21M |
| June 30, 2018 | 152.74M |
| March 31, 2018 | 128.78M |
| December 31, 2017 | 113.21M |
| September 30, 2017 | 101.77M |
| June 30, 2017 | 86.02M |
| March 31, 2017 | 76.95M |
| December 31, 2016 | 72.91M |
| September 30, 2016 | 65.04M |
| June 30, 2016 | 55.55M |
| March 31, 2016 | 54.51M |
| December 31, 2015 | 44.87M |
| September 30, 2015 | 40.57M |
| June 30, 2015 | 36.85M |
| March 31, 2015 | 29.31M |
| December 31, 2014 | 25.91M |
| September 30, 2014 | 20.22M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
214.57M
Minimum
Dec 2019
460.89M
Maximum
Sep 2023
350.75M
Average
362.86M
Median
Sep 2022
Research and Development Expense (TTM) Benchmarks
| Novo Nordisk AS | 6.495B |
| Evaxion Biotech AS | 10.50M |
| Trinity Biotech PLC | 4.366M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 35.08M |